No effect of atypical antipsychotic drugs on weight gain and risk of developing type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimer's disease

Minerva Medica

Volumn 97, Issue 2, 2006, Pages 147-151

  Rondanelli, M ^a,c   Sarra, S ^b   Antoniello, N ^a   Mansi, V ^a   Govoni, S ^b   Falvo, F ^b   Solerte, S B ^b   Ferrari, E ^b  

^a Azienda Servizi alla Persona ASP   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c Istituto di Cura Santa Margherita   (Italy)

Author keywords

Aged; Alzheimer's disease; Antipsychotic drugs; Diabetes mellitus; Lipids

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL;

AGED; ALZHEIMER DISEASE; ANTHROPOMETRIC PARAMETERS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DOSE RESPONSE; DRUG TOLERANCE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; LIPID METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL ASSESSMENT; RISK FACTOR; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; DIBENZOTHIAZEPINES; FEMALE; HUMANS; LIPIDS; MALE; MENTAL DISORDERS; NURSING HOMES; RETROSPECTIVE STUDIES; RISPERIDONE; WEIGHT GAIN;

EID: 33745677489     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. American Psychiatric Association. Work group on Alzheimer's Disease and Related Dementias. Practice Guideline for the Treatment of Patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry 1997;154:1-39.
2. Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer's disease. J Am Psychiatry 1989;146:577-87.
3. Small GV, Rabins PV, Barry PB, Buckholtz NS, DeKosky ST, Ferris SH et al. Diagnosis and treatment of Alzheimer's disease and related disorders: consensus statement of the American Association for geriatric psychiatry, the Alzheimer's Association, and the American Geriatric Society. JAMA 1997;278:1363-71.
4. Rovner BW, Steele CD, German P, Clark R, Folstein MF. Psychiatric diagnosis and uncooperative behavior in nursing homes. J Geriatr Psychiatry Neurol 1992;5:102-5.
5. Victoroff J, Mack WJ, Nielson KA. Psychiatric complication of dementia: impact on caregivers. Dement Geriatr Cogn Disord 1998;9:50-5.
6. Mowat DA, Fowlie D, MacEwan T. CSM warning on atypical psychotics and stroke may be detrimental for dementia. BMJ 2004;328:1262.
7. Smith DA, Beier MT. Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypotheses for an underlying mechanism. J Am Med Dir Assoc 2004;5:129-32.
8. Herrmann N, Lanctot KL. Do atypical antipsychotics cause stroke? CNS Drugs 2005;19:91-103.
9. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712-26.
10. Beasley CM, Sanger W, Satterlee G, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996;124:159-67.
11. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-23.
12. Van Kammen DP, McEvoy JP, Targum S, Kardatzke D, Sebree TB. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl) 1996;124:168-75.
13. Borison RL, Arvanitis LA, Miller BG. ICI204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol 1996;16:158-69.
14. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang R, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002;63:920-30.
15. Mir S, Taylor D. Atypical antipsychotics and hyperglycemia. Int Clin Psychopharmacol 2001;11:25-32.
16. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsycotics. Eur Neuropsychopharmacol 2001;11:25-32.
17. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsycotic. J Clin Psychiatry 2003;64:598-604.
18. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid metabolism. J Clin Psychiatry 2002;63:856-65.
19. Goldberg RJ. Weight variance associated with atypical neuroleptics in nursing home dementia patients. J Am Dir Assoc 2001;2:26-8.
20. Barak J. No weight gain among elderly schizophrenia patients after 1 year of risperidone tretment. J Clin Psychiatry 2002;63:117-9.
21. Etminan M, Streiner DL, Rochon PA. Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults. Pharmacotherapy 2003;23:1411-5.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC: American Psychiatric Association; 1994.
23. Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull 1988;24:653-9.
24. Folstein MF, Folstein SE, McHugh PR. Mini mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
25. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997;48 (5 Suppl 6):S10-6.
26. Frisancho AR. New standards of weight and body composition by frame size and height for assessment of nutritional status of adults and the elderly. Am J Clin Nutr 1984;40:808-19.
27. Vellas B, Guigoz Y, Garry PJ, Nourhashemi F, Bennahum D, Lauque S et al. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition 1999;15:116-22.